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Diﬀerent physiological and pathological conditions can perturb protein folding in the endoplasmic reticulum, leading to a
condition known as ER stress. ER stress activates a complex intracellular signal transduction pathway, called unfolded protein
response (UPR). The UPR is tailored essentially to reestablish ER homeostasis also through adaptive mechanisms involving the
stimulation of autophagy. However, when persistent, ER stress can switch the cytoprotective functions of UPR and autophagy
into cell death promoting mechanisms. Recently, a variety of anticancer therapies have been linked to the induction of ER stress
in cancer cells, suggesting that strategies devised to stimulate its prodeath function or block its prosurvival function, could be
envisaged to improve their tumoricidial action. A better understanding of the molecular mechanisms that determine the ﬁnal
outcome of UPR and autophagy activation by chemotherapeutic agents, will oﬀer new opportunities to improve existing cancer
therapies as well as unravel novel targets for cancer treatment.
1.Introduction
The endoplasmic reticulum (ER) is an organelle with crucial
biosynthetic and signaling functions in eukaryotic cells.
The ER is not only the major intracellular calcium (Ca2+)
storage organelle critically involved in Ca2+ homeostasis and
Ca2+ mediated signaling pathways, but it also provides the
environment for the synthesis, folding, and modiﬁcation of
proteins destined to be secreted or embedded in the plasma
membrane (reviewed in [1, 2]). Moreover, the ER is the
major site for the biosynthesis of steroids, cholesterol, and
lipids. Proper folding, maturation, and stabilization of the
nascent protein in the ER require the highly oxidizing and
Ca2+-rich ER environment, which is essential for the diverse
posttranslational and cotranslational modiﬁcations, includ-
ing glycosylation and disulﬁde bridge formation, to which
proteins are subjected after entering the ER. These processes
are assisted and monitored by several resident chaperones
and Ca2+ binding proteins, including the glucose-regulated
proteins [such as GRP78 or BiP (immunoglobulin heavy-
chain binding protein)], calreticulin and calnexin, and
several folding enzymes, such as the thioredoxin-like protein
disulﬁde isomerase (PDI). PDI oxidizes cysteine residues in
nascent proteins (i.e., oxidative folding) resulting in forma-
tion of intra- and intermolecular disulphide bonds, while
reduced PDI is in turn oxidized by the thiol oxidoreductase
ERO1. ERO1 transfers reducing equivalents to molecular
oxygen, generating stoichiometric amounts of H2O2 per
newly formed disulphide, which is coupled with a depletion
of the reduced gluthatione pool [3]. Proteins that fail to
adopt a correctly folded or native conformation, or a proper
oligomeric assembly in case of multisubunit proteins, are
retrotranslocated to the cytosol through a process known
as ER-associated protein degradation (ERAD), and further
degraded by the 26S proteasome.
Various physiological and pathological conditions,
including hypoxia, ER-Ca2+ depletion, oxidative injury,
high-fat diet, hypoglycemia, and viral infections may cause
an imbalance between ER protein folding load and capacity,
leading to the accumulation of unfolded proteins in the2 International Journal of Cell Biology
ER lumen, a condition referred to as “ER stress”. ER stress
sets in motion an evolutionary conserved and integrated
signal transduction pathway known as the Unfolded Protein
Response (UPR). The UPR primarily aims at ameliorating
theproteinloadontheERbycoordinatingthetemporalshut
down in protein translation along with a complex program
of gene transcription to increase ER folding capacity. If
this transcriptional program fails to reestablish proper ER
homeostasis, persistence in ER stress induces cell death.
SevereERstresscancausecelldeath,usuallybyactivating
intrinsic apoptosis [4]. Moreover, in order to clear the
ER from the accumulation of terminally misfolded protein
aggregates that cannot be degraded by the proteasome,
the UPR may upregulate the autophagy machinery [5, 6].
Macroautophagy (hereafter referred to as autophagy) is
a major lysosomal pathway for the in bulk degradation
of cytoplasmic materials, including proteins and damaged
organelles, characterized by the sequestration of entire
portions of the cytoplasm by a double-membrane bounded
vacuole called the autophagosome [7, 8]. In spite of its
role as a self-digestion mechanism, autophagy is mainly
activated to protect against cell death [8]. However, just like
in the case of the UPR, stimulation of autophagy can under
certain circumstances be required to activate the cell death
machinery [9]. Although both the UPR and autophagy can
function independently from each other, recent reports show
that they may be interlinked and share the functional duality
of exerting both a cytoprotective (under basal or metabolic
stress conditions) and cytocidial activity (after acute cellular
damage).
Tumor cells are bathed in a hostile microenvironment
andconfrontedwithchronicmetabolicstressconditions that
favor the activation of adaptive mechanisms, such as the
UPR and autophagy [10, 11]. Moreover, certain promising
anticancer regimens have been shown to activate concomi-
tantly ER stress and autophagy in cancer cells (see Section 4).
The molecular link between the UPR and the autophagic
response to ER stress, and how these stress pathways inﬂ-
uence therapeutic outcome, remain largely undeﬁned, mak-
ing this topic a very important area for future research in
cancer therapy.
Here, we review the molecular mechanisms underlying
the emerging connections between the UPR and autophagy
pathways,anddiscusstheirpotentialimplicationsinthecon-
text of anticancer therapy.
2. SignalTransduction in ER Stress
2.1. UPR Signaling Pathways. The unfolded protein response
in mammalian cells is governed by three transmembrane
ER stress sensors, namely PERK (PKR-like ER kinase),
IRE1 (inositol requiring enzyme 1), and ATF6 (activating
transcription factor 6), which are kept in an inactive state
by binding to the ER chaperone BiP, preventing their
oligomerization-induced activation. When ER homeostasis
is perturbed, accumulating misfolded proteins become pro-
gressively bound to BiP, titrating away BiP from interaction
with these transmembrane signaling proteins. Upon dein-
hibition and homodimerization these ER sensors activate
a complex ER-to-nucleus signaling pathway that transmits
information across the ER membrane to an extensive
gene-expression program mediated by the activation of
downstream transcription factors. The genetic program
activated by the UPR results in upregulation of the folding
machinery along with an expansion of the ER lumen
and enhanced degradation of terminally misfolded proteins
through ERAD. Additional mechanisms include a general
translational shutdown as well as the degradation of a
select group of secretory mRNAs and proteins that are
delayed at the translocon, a process also known as pre-
emptivequalitycontrol[12].ThemechanismsbywhichUPR
induction coupled with the failure in reestablishing the ER
folding capacity leads to cell death and the requirement of
UPR signaling in autophagy stimulation, are still unsettled
questions. Furthermore, recent studies have revealed that
the ER serves as a subcellular platform for the formation of
signaling complexes comprising molecular elements of the
UPR, Bcl-2 family members (both pro- and antiapoptotic)
(reviewed in [13]), and perhaps regulators of autophagy.
In the following sections we will discuss current knowl-
edge on the main signaling pathways emanating by each
branch of the UPR along with their downstream targets
(Figure 1).
2.1.1. IRE1. Two human isoforms (paralogous) of yeast Ire1
have been identiﬁed. IREα is expressed in all cell types and
tissues,whereasexpressionofIRE1β isprimarilyrestrictedto
the epithelial cells of the gastrointestinal tract [14, 15]. IRE1
is a type I transmembrane protein with an N-terminal lumi-
nal sensor domain and a C-terminal cytosolic eﬀector region
that contains both kinase and endoribonuclease (RNase)
domains [16]. In cells undergoing ER stress, oligomerization
of IRE1 results in trans-autophosphorylation and activation
of the RNase domains which excise a 26nt sequence from
XBP1u (unspliced XBP1), producing mature XBP1s mRNA
(spliced XBP1)[ 17]. XBP1s e n c o d e sa na c t i v el e u c i n e
zipper (bZIP) transcription factor XBP1s that regulates the
transcription of several genes involved in ER quality control
mechanisms, ER/Golgi biogenesis, as well as ERAD compo-
nents [18–22] and as recently revealed, also genes involved in
redox homeostasis and oxidative stress responses [23].
Consistent with this, XBP1 deﬁcient cells were found to
be more susceptible to exogenous agents causing oxidative
stress, such as H2O2 and parthenolide, concomitant with a
reduced expression of several antioxidant enzymes includ-
ing catalase and thioredoxin (TRX1) [24]. Overexpression
of XBP1 restored catalase expression and reduced ROS
generation after H2O2,t h u si m p l i c a t i n gap r o t e c t i v er o l e
for XBP1 in oxidative stress. Intriguingly, this antioxidant
eﬀect was mediated by XBP1u (i.e., the protein encoded
by the unspliced XBP1 mRNA), whereas XBP1s (i.e., the
product of IRE1 activation) failed to induce changes in
catalase expression in response to ROS or following ER
stress, thus underscoring that IRE1 activity is dispensable
[24]. Although the molecular mechanism underlying the
diﬀerential function of the unspliced (XBP1u) and spliced
(XBP1s) products of XBP1 is still elusive- and may involve







































Figure 1: The unfolded protein response in adaptive, apoptotic and redox responses. Upon accumulation of misfolded proteins in the ER,
the release of BiP allows IRE1 and PERK to oligomerize. Oligomerized IRE1 disposes of an intrinsic endoribonuclease activity that mediates
the unconventional splicing of XBP1mRNA which is subsequently translated into XBP1s, a potent transcription factor regulating expression
of genes involved in ERAD and ER quality control. IRE1 signaling is positively regulated by binding of the multidomain proapoptotics
Bax and Bak, while its activity is suppressed by the transmembrane protein BI-1. The interaction of Bax/Bak with IRE1 is required for the
recruitment of TRAF2 and ASK1 leading to the activation of the MAPKs JNK and p38 MAPK, through speciﬁc MKKs. Oligomerized PERK
phosphorylates the translation initiating factor eIF2α, resulting in suppression of general protein translation while favoring the translation
ATF4,which inducestheexpressionofgenes involved inrestoringERhomeostasis.PhosphorylationofNrf2byPERKdisruptsitsassociation
with Keap1 resulting in its nuclear accumulation and upregulation of genes associated with various antioxidant responses. In contrast to
PERK and IRE1, release of BiP from ATF6 induces its translocation to the Golgi where its processing generates an active transcription factor.
Cleaved ATF6 controls mainly genes involved in ERAD and ER homeostasis. Upon severe ER stress, ATF4, XBP1s, and ATF6 can upregulate
the expression of the proapoptotic transcription factor CHOP, which mediates apoptosis by the upregulation of proapoptotic BH3-only
protein Bim and by suppressing Bcl-2 expression. CHOP activity is enhanced through phosphorylation by p38MAPK. Phosphorylation by
JNK in turn activates Bim while inhibiting Bcl-2 functions.
on their relative abundance in diﬀerent cell types [23] this
study highlights a new role for XBP1 in ROS signaling, inde-
pendent of IRE1 RNase activity.
Although IRE1 displays intrinsic kinase activity, there
are no other substrates known thus far than IRE1 itself.
However, prolonged activation of IRE1 is capable to transmit
a MAP kinase activation cascade. It has been shown that
IRE1 can serve as a molecular platform for the recruitment
of the adaptor protein TNF-receptor associated receptor 2
(TRAF2),anE3ubiquitinligase,whichleadstotheactivation
of apoptosis signal regulating kinase 1 (ASK1), a MAP3K
of the JNK/p38 MAPK pathway [25, 26]. Depending on
the cellular context, activation of JNK can either allow
the cells to adapt to ER stress by initiating autophagy [5]
or, as discussed further, promote apoptosis in response to
persistent or irrecoverable ER stress.
2.1.2. PERK. L i k eI R E 1 ,P E R Ki sat y p eIt r a n s m e m b r a n e
protein with a luminal sensing domain and a cytosolic kinase
domain which becomes activated following dimerization.
The resulting transautophosphorylation induces a confor-
mationalchangethatenhancestheaﬃnityofPERKforeIF2α
(eukaryotic initiation factor 2 alpha) [27]. Phosphorylation
of eIF2α on Ser51 by PERK results in the rapid shut down
of general translation, relieving the protein burden on the
stressed ER, while the concomitant loss of cyclin D1 arrests
the ER stressed cells in G1. In addition, a recent study has
shown that eIF2α phosphorylation also regulates translation
via inhibition of rRNA synthesis, coordinately regulating
translation and ribosome biogenesis during cellular stress
[28]. Paradoxically, this translational shutdown leads to
the selective translation of the transcription factor ATF4, a
member of the bZIP family of transcription factors [29].4 International Journal of Cell Biology
The PERK-eIF2α-ATF4 axis regulates the expression of genes
involved in amino acid biosynthesis and transport functions,
antioxidant stress responses, and apoptosis.
In addition to eIF2α, PERK also phosphorylates the
Nuclear factor-E2-related factor 2 (Nrf2) [30]. Nrf2 is a bZIP
Cap ‘n Collar transcription factor that integrates a variety
of cellular responses to oxidative stress. Nrf2 is maintained
inactive in a cytoplasmic complex with the microtubule
associated protein KEAP1 (Kelch-like Ech-associated protein
1). Nrf2 phosphorylation promotes its dissociation from
KEAP1,leadingtothenuclearaccumulationofNrf2,binding
the antioxidant response element (ARE) in the promotor of
genes encoding detoxifying enzymes such as heme oxygenase
1 (HO-1) [31]. In line with these results, it was shown that
Nrf2−/− cells are more prone to ER stress induced apoptosis
[30]. Likewise, PERK
−/− cells, along with an impaired atte-
nuation of protein synthesis, were found to mount a
high amount of endogenous peroxides preceding apoptotic
induction in response to agents causing perturbation of ER
functions [32]. Interfering with ERO1 blocked the increased
ROS production, thus providing a link between protein
oxidation in the ER and ROS production during ER stress.
This PERK function was linked to the ability of ATF4 to
regulate the expression of genes involved in glutathione
biosynthesis and antioxidant response [32]. These studies
suggest that the PERK branch of UPR bifurcates in two
parallel but integrated signaling pathways, PERK-eIF2α-
ATF4 and PERK-Nrf2, with a key role in adaptation to
oxidative stress, a metabolic consequence of biosynthesis and
posttranslational oxidative processing in the ER.
2.1.3. ATF6. Both isoforms of ATF6, ATF6α and ATF6β,
are present in all cell lines as type II transmembrane ER
proteins. Release of BiP does not cause ATF6 oligomer-
ization, but instead reveals a Golgi localization sequence
[33]. Once translocated to the Golgi, ATF6 is cleaved at
a juxtamembrane site by the site 1 and site 2 proteases
(S1P and S2P) [34], which are also involved in the cleavage
of the ER membrane transcription factor SREBP (sterol
response element-binding protein) [35, 36]. Processed ATF6
moves to the nucleus where it forms active homodimers or
dimerizes with other bZIP transcription factors like NF-Y
(CAAT binding factor) as well as XBP1s [37], to regulate
transcription from ATF/cAMP response elements (CREs)
and ERSEs [38;39]. One of the ATF6 transcriptional targets
is the IRE1 substrate XBP1 [22]. Interestingly, Yoshida
et al. found that XBP1u interacts directly with the active
form of ATF6 (but not ATF4), targeting it for proteasomal
degradation which may provide a negative feedback loop
to decrease XBP1 expression [38]. Other transcriptional
targetsincludeproteinsincreasingERchaperoneactivityand
degrading of ER client proteins [37, 39]. Although ATF6
is neither essential for basal expression of ER chaperones
nor for embryonic or postnatal development, it plays an
important rolein recoveryfromacuteER stressand adapting
cells to chronic ER stress [39]. Additionally, a recent study
showsthatATF6αalsocontributes,inanXPB1s-independent
manner, to lipid biogenesis and ER expansion, an ER stress
response which was thought to be predominantly mediated
by the IREI pathway [40].
2.2. Regulation of the UPR by Bcl-2 Family Members. Bcl-
2 family proteins, which consist of proapoptotic multido-
main proteins (e.g., Bax, Bak), antiapoptotic multidomain
proteins (e.g., Bcl-2), and BH3-only proteins (e.g., Bid,
Bim, Bad), are key regulators of mitochondrial apoptosis
[41, 42]. They function as gatekeepers (antiapoptotic; Bcl-2)
or gatecrashers (proapoptotic; Bax/Bak) of the outer mito-
chondrial membrane [43]. While the molecular mechanism
underlying their mitochondrial action is still a matter of
debate, it is becoming clear that Bcl-2 family proteins can
e x e r tat i g h tc o n t r o lo na p o p t o s i sa td i ﬀerent subcellular
sites. A constellation of ER localized Bcl-2 family members,
including Bax, Bak, Bik/Nbk, and Bcl-2, has been shown
to be engaged in the control of ER-Ca2+ homeostasis [44–
46] (for an extensive review see [13, 47]). Moreover, recent
r e p o r t sh a v ei d e n t i ﬁ e dB c l - 2m e m b e r sa sv i t a lr e g u l a t o r so f
UPRsensormechanismsandcellularfatefollowingERstress.
For instance, ATF6 negatively regulates Bad proapoptotic
activity by upregulating regulator of calcineurin 1 (RCAN1)
[48], an endogenous inhibitor of calcineurin (protein phos-
phatase B). Bad dephosphorylation allows its dimerization
with antiapoptotic Bcl-2 protein family members like Bcl-Xl,
thus inhibiting their activity [49]. This mechanism under-
scores a prosurvival role for the genetic program activated by
ATF6, through the suppression of Bad proapoptotic activity
[49].
The proapoptotic multidomain proteins Bax and Bak
can form a protein complex with the cytosolic domain of
IRE1, and this interaction has been shown to be essential
for IRE1 signaling [50]. Genetic ablation of bax/bak in
mice caused abnormal response to tunicamycin-induced
ER stress in the liver along with extensive tissue damage,
decreased expression of XBP1, and reduced JNK activation
[50]. Furthermore, the requirement of Bax/Bak proteins
for proper IRE1 signaling was conﬁrmed in MEFs doubly
deﬁcient (DKO) in these proapoptotic proteins [50]. In a
recent report Klee et al. [51] showed that reconstituting Bak
expression at the ER membranes in DKO cells is suﬃcient
to reestablish IRE1-TRAF2 activation and mitochondrial
apoptosis (as discussed further in Section 2.3) instigated by
reticular forms of the BH3-only proteins Bim and Puma.
Interestingly, the IRE1 pathway activated by reticular BH3-
only eﬀectors was atypical as it did not lead to XBP1
splicing, likely because other arms of the UPR required for
the upregulation of XBP1 mRNA levels, such as ATF6, were
not suﬃciently activated [51]. However, an alternative and
intriguing possibility could involve a diﬀerential regulation
of the IRE1 RNase activity (required for XBP1 mRNA
splicing) and IRE1-TRAF2 complex formation (required to
activate proapoptotic JNK signaling) by a diﬀerent subset of
proapoptotic proteins at the ER membrane. Clearly, further
studies are required to shed more light into the mechanisms
regulating IRE1 signal transduction.
Recently, the ER associated Bax inhibitor-1 (BI-1), an
evolutionary conserved antiapoptotic protein, has been
identiﬁed as a new player in the regulation of IRE1 by Bcl-2International Journal of Cell Biology 5
family members and their modulators. BI-1 can block Bax-
mediated apoptosis following ER stress and other intrinsic
stress signals by directly interacting with antiapoptotic Bcl-2
family members and enhancing their antiapoptotic function
[52]. BI-1 at the ER was found to be capable to interact
through its C-terminus domain with IRE1 and to inhibit
IRE1 signaling, in vitro as well as in mice and ﬂies,
conferring increased resistance under conditions of mild
ER stress [53]. ER stressed BI-1 deﬁcient cells displayed
IRE1 hyperactivation along with an increased XBP1 mRNA
splicing and expression of XBP1s-dependent genes, thus
unraveling a paradoxical role of BI-1 as inhibitor of the
cytoprotective IRE1 branch of the UPR in mildly ER
stressed cells. Interestingly, in another study using human
ﬁbrosarcoma cells, overexpression of BI-1 inhibited ROS
production downstream ER stress through the upregulation
of HO-1, an eﬀector of the PERK-pathway (as described
previously) [54]. Although in the study of Lisbona et al.
[53] BI-1 deﬁciency in MEFs did not aﬀect expression of
HO-1, this raises the intriguing possibility that BI-1 may
aﬀect IRE1 and possibly PERK pathway in a cell type speciﬁc
manner. Whereas further mechanistic studies are required to
solve these discrepancies, these ﬁndings reveal how a subtle
cross-talk between molecular sensors of UPR and cell death
regulators might aﬀect the amplitude and function of the
UPR. Moreover, abundant evidence claims for a critical role
of proapoptotic Bcl-2 family proteins in the induction of
apoptosis following ER stress.
2.3. From ER Stress to Cell Death. When the initial cellular
responses fail to restore ER homeostasis, sustained ER stress
causes the UPR to switch from an adaptive to a cell death
pathway. However, the molecular elements of this switch are
still elusive. With the exception of few components of the
UPR for which a dominant prosurvival (i.e., BiP, [55]) or
proapoptotic (i.e., CHOP, [56, 57]) role has been assigned
by genetic studies, each apical UPR sensor holds a dualistic
role in propagating adaptive as well as a toxic signals.
For example, genetic deletion of PERK or interference
witheIF2αphosphorylationimpairscellsurvival[58,59]and
tumor growth under hypoxia [60], while artiﬁcially increas-
ing PERK activity increases cell survival [61]. However, Lin
etal.[62]haveshownthatsustainedPERKsignalingislethal,
whereas the equivalent duration of IRE1 signaling is not,
suggesting that transition from protective to proapoptotic
UPR function involves a switch in IRE1 signaling along with
enduring PERK activity [62].
The main eﬀector of PERK-mediated apoptosis is the
proapoptotic transcription factor CHOP (C/EBP homolo-
gous protein; GADD153) which can be induced by ATF4,
ATF6, as well as XBP1s. However, the PERK-eIF2α branch
appeared to be essential for CHOP upregulation as both
PERK
−/−,A T F 4 −/− and eIF2α Ser51Ala knock-in cells failed
to induce CHOP during ER stress [32, 58, 59]. CHOP
activity is also regulated translationally by the limited CHOP
mRNA lifetime [63] and posttranslationally by p38MAPK
phosphorylation, which enhances its proapoptotic activity
[57, 64]. The latter mechanism may provide a point of
convergence between the PERK and IRE1 signaling pathways
since p38MAPK is a downstream target of the IRE1-TRAF2-
ASK1 signaling complex [25, 26]. Genetic studies have
shown that CHOP loss-of-function results in cytoprotection,
whereas CHOP gain-of-function enhances sensitivity to a
variety of stresses perturbing ER function [56, 65].
CHOP mediated cell death entails the induction of a
variety of genes that may potentiate apoptosis, including
GADD34, ERO1α, Bim,a n dTRB3 (Tribbles homologue 3).
GADD34 is a regulatory subunit of protein phosphatase
1 (PP1) that targets PP1 to dephoshorylate eIF2α,w h i c h
promotes the resumption of protein synthesis [66]. If the
protein folding capacity of the ER has not been reestablished,
a premature deinhibition of translation will increase client
protein load in the ER and may favor improper disulphide
bond formation of unfolded proteins, thus amplifying the
damage. In addition, elevated expression of ERO1α by
CHOP is thought to instigate hyperoxidizing conditions in
the ER [67, 68]. Thus the PERK-axis, which is involved in
maintaining the redox state during ER stress, as discussed
before, has also the ability to turn into a prooxidant signal
when the transcriptional program of CHOP is eﬃciently set
in motion.
As suggested by a recent study wherein the stability of
prosurvival and prodeath mRNAs and proteins was studied
under conditions of mild or severe ER stress [63], ATF4-
dependent prosurvival gene expression is likely to be more
sustained when PERK is activated transiently and to a
limited extent. In contrast, as a consequence of the intrinsic
instability of the proapoptotic mRNAs and proteins, the
apoptotic program mediated by the ATF4 target CHOP
wouldbeactivatedonlywhenprotectivemechanismsfailand
require a more sustained PERK activation.
CHOP can also regulate the expression of a number of
Bcl-2 family proteins. By a yet unidentiﬁed mechanism, it
suppresses the expression of the antiapoptotic Bcl-2 [65]
while directly promoting the transcription of the proapop-
totic BH3-only protein Bim [69].
Although it is clear that CHOP fulﬁlls an important role
in ER stress induced apoptosis, the fact that PERK
−/− and
eIF2α Ser51Ala knock-in cells are unable to induce CHOP
yet are very susceptible to ER stress [58, 59] unravels the
dual role of the PERK axis in triggering both adaptive and
proapoptotic processes. The increased sensitivity of PERK
deﬁcient cells could be explained, at least in part, by the
impaired activation of the prosurvival PI3K (phosphatidyli-
nositol 3 kinase)-Akt signaling pathway which has been
shown to promote the expression of inhibitor of apoptosis
proteins (IAPs), thus conferring cellular resistance to ER
stress [70, 71].
An interesting molecular switch between the prosurvival
and prodeath functions of the PERK pathway could involve
the human orthologue of the Drosophila tribble protein
(TRB3), a downstream transcriptional target of CHOP
[72]. Ohoka and et al. [72] showed that TRB3 knock
down sensitized the cells to cell death during tunicamycin
treatment. Remarkably, TRB3 could downregulate its own
induction by repressing CHOP/ATF4 functions [72, 73]. A
mechanism was proposed wherein TRB3 exerts a negative
feedbackonCHOPduringmildERstress,allowingthecellto6 International Journal of Cell Biology
adapt to ER stress [72, 73]. In contrast, during severe or per-
sistent ER stress, induction of TRB3 would be more robust,
leading to apoptosis through a mechanism involving TRB3-
mediated inhibition (dephosphorylation) of Akt [74, 75].
This feedback mechanism could facilitate ER stress mediated
apoptosis in severely ER stressed cells that have successfully
mounted proapoptotic threshold levels of CHOP.
Similar to PERK, IRE1 signaling has also been implicated
in promoting or impairing cell survival. For instance, when
unfolded proteins accumulate, artiﬁcially extending IRE1’s
RNase function led to enhanced survival [62, 76]a n d
the knock down of XBP1 impaired cell survival, [77, 78]
pointing to a general protective role for the IRE1-XBP1
signaling during ER stress. However, in another report, IRE1
overexpression in HEK293T cells led to its activation in
the absence of ER stress and subsequent cell death [14].
As discussed before, IRE1 has apparently gained signaling
properties independent of XBP1 splicing, which are strongly
dependent on interaction with Bcl-2 proapoptotics and Bcl2
modulators at the ER membrane. Thus, IRE1 can promote
cell death by recruiting a TRAF2-ASK1 complex leading to
the activation of JNK and p38 MAPK cascades [25, 26]. JNK,
in turn, can exert its proapoptotic eﬀect by activating certain
BH3-only proteins, such as Bim [79, 80], or by suppressing
the antiapoptotic activity of Bcl-2 [81].
The apoptotic pathway evoked after UPR is still unclear,
but mounting observations indicate that the mitochondrial
pathway is heavily involved, since cells lacking Bax and
Bak, or Apaf-1 are resistant to apoptosis induction by
diﬀerent ER stressors [44, 82, 83]. Moreover, as mentioned
before, several Bcl-2 family members localize at the ER and
regulate both calcium levels as well as signal transduction
through the UPR. In addition to Bim, other BH3-only
proteins, such as Noxa and Puma, are transcriptionally
activated, through p53-dependent [84] and independent
mechanisms [85] depending on the type of ER stressor,
thus bridging ER stress to Bax/Bak mediated mitochondrial
membrane permeabilization. Recently Klee and coworkers
usingBax−/−/Bak
−/− cellsshowedthatBaktargetedattheER
membrane is suﬃcient to engage mitochondrial apoptosis
when activated by BH3-only molecules Puma and Bim at
the ER, thus bypassing the need to be localized to the
mitochondria [51]. Reticular Bak engaged an atypical IREα-
TRAF2 activation pathway, wherein the mobilization of Ca2+
facilitated persistent JNK activation [51]. Intriguingly, ER
Ca2+ release per se was not able to incite mitochondrial
apoptosis unless Bak was expressed at the reticulum [51],
whereas it favored nonapoptotic cell death, as shown also
in our previous study [82]. Whether this pathway has any
role in normal cells expressing both mitochondrial and ER
Bax/Bak still needs to be proven, however it can already be
argued that JNK functions as a master regulator of both
apoptosis and perhaps autophagy pathways after ER stress.
Thus all together the emerging consensus is that the
amplitude and the temporal activation of speciﬁc arms of the
UPR,alongwiththerepertoireofsignalingplatformsformed
attheERmembrane(UPRinteractome),arecrucialelements
determining cellular fate following ER stress.
3. ER Stress andAutophagy
3.1. Autophagy. Proteasomal degradation and autophagy are
the two main mechanisms that are in charge of protein
clearance in the cell. Unlike proteasomal degradation (that
digests soluble ubiquitin-conjugated proteins in a speciﬁc
way), autophagy can degrade both soluble and aggregated
proteins [8, 86]. Thus, during the autophagic process,
entire cytoplasmic portions—including organelles and other
cytoplasmic components—are engulfed within a double
membrane vesicle designated autophagosome. The matura-
tion of these vesicles involves their fusion with lysosomes,
whichleadsinturntothedegradationoftheautophagosome
components by the lysosomal degradative enzymes [8, 86].
As discussed below, a variety of stress signals such as
nutrient starvation or treatment with diﬀerent anticancer
agents (including those that induce ER stress) stimulate
the autophagy process—which is nowadays considered as
an essential cellular process participating in a number of
physiological functions within the cell.
The molecular mechanisms responsible for the regu-
lation of autophagy have not been completely elucidated
yet, although genetic and biochemical analyses performed
during the last few years have identiﬁed several autophagy
genes (Atg) that participate in the regulation of this cellular
process. Researchers working in the autophagy ﬁeld have
formally divided the autophagic process in several steps.
Initiationofautophagyreliesontheformationofanisolation
membrane (IM) at the so-called preautophagosomal site.
Elongationofthisisolationmembraneleadstotheformation
of the autophagosome. The autophagy process ends with the
fusionoftheautophagosomeandthelysosome,thedigestion
oftheautophagosomecontent,andthereleaseofthedigested
components back to the cytosol [8, 86]. In these sections,
we will brieﬂy summarize the mechanisms by which the
diﬀerent stages of autophagy are regulated.
The normal rate of autophagy in the cell is low and
therefore this cellular process only becomes activated in
response to certain situations. Thus, exposure of the cell to
an autophagic stimulus triggers a series of modiﬁcations in
theautophagicmachinerythatallowtheformationandelon-
gation of the IM. The precise origin of the IM in mammalian
cells is still unknown, although it has been proposed that
it could be either derived from de novo synthesized lipids
or generated by vesicle budding from ER, Golgi apparatus,
or endosomes [87]. The transmembrane proteins Atg9 and
VMP-1 [88, 89] are required for autophagosome formation
and it has been suggested that they could play a role in the
transport of lipids to the IM as well as in the recruitment of
additional proteins involved in the initiation of autophagy.
Thus, the movement of Atg9 from the trans-Golgi location
to the preautophagosomal site seems to be a crucial event in
the initiation of autophagy [87, 90].
The relocation of the transmembrane protein Atg9 to
the autophagosome is thought to require activation of
the complex formed by the proteins Atg1, Atg13, and
Atg17/FIP200.[88].The activity of the Atg1 complex is
modulated by the mammalian target of rapamycin complex
1 (mTORC1). mTORC1 is a protein complex formed byInternational Journal of Cell Biology 7
mTOR, RAPTOR (regulatory associated protein of mTOR),
mLST8, and PRAS40 (proline-rich AKT substrate 40kDa)
[91] that plays a central role in the control of protein
synthesis, cell growth, and cell proliferation through the
regulation of several downstream targets [91]. In addi-
tion, mTORC1 has been proposed to regulate autophagy
by repressing the activity of the Atg1-Atg13-Atg17/FIP200
complex[92–95].Thus,inhibitionofmTORC1facilitatesthe
initiation of autophagy. Regulation of mTORC1 relies on the
small G protein Rheb (ras homologue enriched in brain)
which(throughastillnotcompletelyelucidatedmechanism)
activates mTORC1. The tuberous sclerosis proteins (TSC1
and TSC2) have GTPase activating protein (GAP) activity
on Rheb and therefore promote its inhibition. Hence,
inactivation of TSC1/2 stimulates Rheb and mTORC1 and
inhibits autophagy [91].
As a result of its central position in the control of cellular
homeostasis, mTORC1 integrates signals from diﬀerent
inputs. One of the most important upstream regulators of
mTORC1 is the prosurvival kinase Akt, which phosphory-
lates and inactivates TSC2 as well as PRAS40 [91]. Thus,
Akt activation stimulates mTORC1 and inhibits autophagy.
Another important regulator of TSC2 is the AMP-activated
protein kinase (AMPK) which phosphorylates TSC2 in a
diﬀerent residue than Akt leading to activation of TSC1/2,
inactivation of Rheb, and inhibition of mTORC1 [96]. As
discussed in the following sections, modulation of mTORC1
activity is one of the mechanisms by which ER stress and
autophagy become connected.
Another important step in the initiation of autophagy
is the generation of a speciﬁc pool of phosphatidylinositol-
3-P (PIP3) at the autophagosome. In mammals, this event
is catalyzed by the class III phosphatidylinositol 3 kinase
(PI3K) complex [which consists of Vps34 (vacuolar protein
sorting 34) and its regulatory protein p150 (homolog to the
yeast Vps15 protein)] [97]. Accumulation of PIP3 seems to
be crucial for the recruitment of autophagy proteins such
as Atg18/WIPI-1 to the IM which is important for Atg9
traﬃcking and therefore for the initiation of the autophagic
process [90]. In addition, other proteins such as mAtg2 and
DFCP1 (double FYVE domain-containing protein 1) may
also be regulated by PIP3 and play a role in the regulation
of the formation and elongation of the autophagosome
[90]. Underlining the importance of PIP3 in the early stage
of autophagy, a speciﬁc phosphoinositide 3-phosphatase
(Jumpy)hasbeenveryrecentlyidentiﬁedasanewmodulator
of this cellular process [98].
Importantly, other Vps34-interacting proteins are requ-
ired for autophagy including, Vps30/Atg6/Beclin1, Atg14
and autophagy/beclin-1 regulator 1 (Ambra-1), and UVRAG
[86]. Among the diﬀerent partners of Vps34, particular
attention has been focused on Beclin-1. Beclin-1 has a BH3-
only domain that permits the interaction of this protein
with the antiapoptotic proteins Bcl-2 and Bcl-XL. This
interaction abrogates Beclin-1 ability to induce autophagy
[99–102]. Diﬀerent stimuli, including ER stress, modulate
the interaction between Beclin-1 and Bcl-2 family members
(see also the following sections) which is considered an
important mechanism of autophagy regulation.
Atg14andUVRAGarealsointeractorsofVps34although
their presence in the class III PI3K complex seems to be
mutually exclusive [87, 103, 104]. Recent ﬁndings support
that Atg14 plays an important role in the early stages of
autophagy activation in response to starvation [87]. In any
case, further research is still necessary to understand the
complex lipid-protein and protein-protein interactions that
regulate the formation of the IM.
The elongation of the initial autophagic membrane
requires the participation of two ubiquitin-like protein
conjugation systems which modify the autophagy proteins
Atg5andAtg8/LC3.Thus,uponautophagystimulation,Atg5
is conjugated to Atg12. In this process Atg12 is activated by
the E1 activating enzyme Atg7 and transferred to the E2-
like protein Atg10. Finally Atg12 is attached to an internal
lysine of Atg5 in a process that does not seem to require
an E3 ligase protein. The Atg5-Atg12 conjugation complex
interacts with Atg16L to form the Atg16L complex [87].
The other conjugation system involves the modiﬁcation of
Atg8/LC3. Initially Atg8/LC3 is cleaved by the protease Atg4
(which generates a glycine Ct residue in Atg8/LC3). Then,
the E1 enzyme Atg7 activates Atg8, which is transferred
to the E2-like protein Atg3. The last step in Atg8/LC3
modiﬁcation involves the conjugation of this protein to
phosphatidylethanolamine (PE), a process that is facilitated
by the E3-like activity of the Atg12-Atg5 conjugate [105,
106].Uponautophagyinduction,mostofAtg8/LC3becomes
lipidated and associates with the autophagosome, which
is widely used to monitor activation of autophagy by
immunoﬂuorescence [8, 86, 107]. The Atg16L and Atg8/LC3
complexes play a crucial role on the modiﬁcation of the
autophagosomal membrane and therefore in the elongation
and closure of the autophagosome
The laststepintheautophagicprocessis thefusionofthe
autophagosome with lysosomes. The canonical machinery
of vacuole membrane fusion seems to participate in the
regulation of this process [87, 90]. Thus, the lysosomal
protein LAMP2 and the small GTPase Rab7 have been impli-
cated in autophagosome-lysosome fusion in mammalian
cells. Nevertheless, many additional proteins including those
belonging to the Rab and soluble N-ethylmaleimide sensitive
factor attachment protein receptors family (SNARE) are
believed to play an important role in the autophagosome-
lysosome fusion process [8, 86]. The lysosomal degradation
of the autophagosomal content relies on several lysosomal
hydrolases including cathepsins B, D, and L.
The ﬁnal outcome of the activation of the autophagy
program is highly dependent on the cellular context and the
strength and duration of the stress-inducing signals. Thus,
besides its role in cellular homeostasis, autophagy can be
a form of programmed cell death or play a cytoprotective
role, for example in situations of nutrient starvation [108,
109]. Accordingly, autophagy plays a dual role in cancer.
On one hand, this cellular process may help to overcome
the stress evoked by the lack of nutrients and oxygen
at the initial steps of tumorigenesis. On the other hand,
autophagy has been proposed to play a tumor suppressor
function by providing the minimal supply of ATP required
for DNA repair, preventing oxidative stress and reducing8 International Journal of Cell Biology
intratumoral necrosis and local inﬂammation [110–113].
Moreover, diﬀerentanticancertreatmentsactivateautophagy
in tumor cells, which has been proposed to either enhance
cancer cell death or act as a mechanism of resistance to
chemotherapy [110–115].
3.2.ConnectingERStressResponsesandAutophagy. Diﬀerent
situations that induce ER stress also lead to induction
of autophagy. As discussed above, the ER stress response
is activated to protect the cells from diﬀerent alterations
aﬀecting this organelle. However, when the intensity or
duration of the ER damage cannot be restored by this
response,ERstresscanalsoleadtocelldeath[116].Likewise,
autophagy can help cells to cope with ER stress (for instance
contributing to the elimination of unfolded or aggregated
proteins) or participate in the mechanism of ER stress-
induced cell death [115, 117–119]. In this section we will
try to delineate some of the proposed mechanisms by which
ER stress and autophagy become connected under certain
cellular situations (Figure 2).
3.2.1. UPR and Autophagy. As described above, the accumu-
lation of unfolded proteins triggers the UPR thus promoting
the inhibition of general protein synthesis as well as the
increased translation of several transcription factors that
enhance the expression of ER stress genes [117] (see the
previous sections for further details). Evidence for a link
between UPR and autophagy was obtained from ectopic
expression of polyglutamine (polyQ) proteins [6]. In these
experiments, a dominant-negative form of PERK or genetic
substitution of Serine 51 of eIF2α by Ala (which prevents the
phosphorylation of this protein) prevented polyQ protein-
induced autophagy [6], strongly suggesting that PERK-
dependent eIF2α phosphorylation plays an important role in
the activation of autophagy in response to the accumulation
ofunfoldedproteins.Ontheotherhand,eIF2αphosphoryla-
tion seems to be also important for autophagy as induced by
other ER stress-related or unrelated stimuli [75, 120, 121]. It
is important to bear in mind that PERK is not the only pro-
tein kinase regulating eIF2α phosphorylation (see reference
[116] for a review) as double-stranded RNA-activated pro-
tein kinase (PKR; activated in viral responses), general con-
trol nonderepressible 2 (GCN2; activated upon aminoacid
starvation), and heme-regulated inhibitor (HRI; activated
in heme depletion) also phosphorylate eIF2α.A c c o r d -
ingly, PKR-dependent eIF2α phosphorylation modulates
autophagy in response to viral infection [120]. Likewise, the
small heat shock 22KDa protein 8 (HspB8) and its cochap-
erone Bcl-2-associated athanogene 3 (Bag3) have been
proposed to mediate mutated hungtingtin-induced eIF2α
phosphorylation and autophagy via GCN2 activation [121].
Regarding the signalling pathways by which eIF2α phos-
phorylation can modulate autophagy, Kouroku and et al.
showed that PERK-eIF2α-dependent Atg12 upregulation is
required for induction of autophagy in response to polyQ
protein accumulation [6]—which suggests that controlling
the expression of autophagy-related genes by eIF2α down-
stream targets could be one of the mechanisms connecting
both events. On the other hand, we have recently found
that treatment of cancer cells with Δ9-tetrahydrocannabinol
(THC), the active component of marihuana, activates
autophagy via ER stress and eIF2α phosphorylation [75]( a n
eﬀect that is not mediated by PERK, PKR, or GCN2, Salazar,
M. and Velasco, G. unpublished observations). Our data
indicate that induction of autophagy in response to THC
treatment relies on the eIF2α phosphorylation-dependent
upregulation of the transcription factors p8, ATF-4, and
CHOP as well as of the pseudokinase TRB3 (four genes
that had been previously identiﬁed as essential mediators
o fT H Ca c t i o ni nc a n c e rc e l l s[ 122, 123]). We also showed
that an important step in the induction of autophagy is the
inhibition of the Akt/mTORC1 axis by the pseudokinase
TRB3 [75] (see below for additional details) (Figure 2).
In any case, further research is still necessary to clarify
the precise mechanisms by which eIF2α phosphorylation
regulatesautophagyinresponsetodiﬀerentERstresssignals.
Activation of the IRE1 arm of the ER stress response
has also been shown to regulate autophagy. Thus, treatment
with tunicamycin or thapsigargin [5]o rt r e a t m e n tw i t h
proteasome inhibitors [119] induced autophagy on an IRE1-
dependent manner. The proautophagic actions of IRE1 seem
to rely on the ability of this protein to interact with the
cytosolic adaptor TRAF-2 and activate JNK) [5]. Of interest,
JNK has been proposed to regulate autophagy through Bcl-2
phosphorylation, which prevents this protein of interacting
(and inhibiting) the essential autophagy regulator Beclin-1
[99, 124, 125]. In addition, JNK has been shown to control
Beclin-1 expression to regulate ceramide-induced autophagy
[126]. As discussed above, Beclin-1 is associated to the
Vps34 and plays a very important role in the regulation
of autophagy ([102]see below) (Figure 2). It is therefore
conceivable that activation of the IRE1/TRAF2/JNK arm of
ER stress may regulate autophagy through modulation of
Beclin-1 function and expression. Intriguingly, it has been
recently shown that XBP-1 ablation increases autophagy and
protects from the toxicity induced by the aggregates of the
enzyme superoxide dismutase 1 in a model of Amyotrophic
lateral sclerosis [127]. These observations suggest that the
XBP-1 may play a diﬀerent role than TRAF2/JNK on the
regulation of autophagy by the Ire1 arm of the UPR.
3.2.2. Ca2+ Signalling and Autophagy. ER stress activation is
frequently accompanied by calcium release into the cytosol
which leads to the activation of several Ca2+-regulated
signalling pathways [116]. Diﬀerent agents (including ER
stress inducers) have been shown to produce an increase in
cytosolic calcium concentration and activate autophagy. One
of the mechanisms connecting Ca2+ release from the ER and
autophagy is the stimulation of AMPK [128]. As explained
above, several kinases regulate mTORC1 including AMPK,
which inhibits mTORC1 by activating TSC2 [129]. AMPK
is considered an important energy sensor that becomes
activated upon ATP cellular depletion or phosphorylation by
diﬀerent kinases [96]. Three AMPK upstream kinases have
been identiﬁed to date: LKB1, Ca2+/calmodulin-dependent
kinase kinase β (CaCMKKβ), and transforming growth




































Figure 2: Mechanisms connecting ER stress and autophagy. Diﬀerent ER stresses lead to autophagy activation. Ca
2+ release from the ER
can stimulate diﬀerent kinases that regulate autophagy. CaCMKKβ phosphorylates and activates AMPK which leads to mTORC1 inhibition;
DAPK phosphorylates Beclin-1 promoting its dissociation from Bcl-2; PKCθ activation may also promote autophagy independently of
mTORC1.Inositol1,4,5-trisphosphatereceptor(IP3R)interactswithBeclin-1.PharmacologicalinhibitionofIP3Rmayleadtoautophagyin
aC a
2+-independent manner by stimulating its dissociation from Beclin-1. The IRE1 arm of ER stress leads to JNK activation and increased
phosphorylation of Bcl-2 which promotes its dissociation from Beclin-1. Increased phosphorylation of eIF2α in response to diﬀerent ER
stress stimuli can lead to autophagy through ATF4-dependent increased expression of Atg12. Alternatively, ATF4 and the stress-regulated
protein p8 promote the up-regulation of the pseudokinase TRB3 which leads to inhibition of the Akt/mTORC1 axis to stimulate autophagy.
coworkers showed that increases in cytosolic Ca2+ concen-
tration upon treatment with diﬀerent ER stress inducers
stimulate CaMKKβ, leading in turn to AMPK activation,
inhibition of mTORC1, and autophagy stimulation [128].
The same group has recently shown that TRAIL-induced
autophagy is also mediated by AMPK, in this case through
a mechanism that involves phosphorylation of AMPK by
TAK1 and not by LKB1 or CaM-KKβ [130]. These obser-
vations suggest that AMPK may play an important role in
the regulation of autophagy in response to diﬀerent Ca2+-
dependent and independent stress signals.
Another Ca2+-activated kinase that regulates autophagy
in response to ER stress is the death associated protein kinase
1 (DAPK). DAPK is a Ser/Thr kinase that plays an important
role as tumor suppressor due to its ability to promote
apoptosis and autophagy [131]. Thus, DAPK-deﬁcient MEFs
are less sensitive to ER stress-induced autophagy than their
wild-type counterparts [132]. Activation of DAPK upon
ER stress relies on the dephosphorylation of an inhibitory
autophosphorylation site of the kinase by a PP2A phos-
phatase [132], which suggests that additional ER stress-
activated signals (apart from Ca2+ release) are required to
stimulate the proautophagic activity of the kinase. Regarding
the mechanisms by which DAPK regulates autophagy, it has
been recently shown that DAPK phosphorylates Beclin-1 on
the BH3-only domain preventing thus the interaction of this
protein with Bcl-2 [133, 134]. In addition, DAPK regulates
p53 in a p19Arf-dependent manner [135]. As p53 modulates
autophagy through diﬀerent mechanisms [112, 136–138],
this could be another way by which DAPK could regulate
autophagy in response to certain ER stress stimuli.
The protein kinase C theta (PKCθ) has been also
implicated in regulating autophagy in response to ER stress
inacalcium-dependentmanner.Thus,knock-downofPKCθ
(butnot inactivation of the UPRsignalling routes)prevented
autophagy as induced by acute ER stress [139]. In this study,
inactivation of mTORC1, under the used concentrations






















Figure 3: Hypothetic therapeutic strategies based on the modulation of ER stress and autophagy. Diﬀerent strategies involving modulation
of ER stress and autophagy could be potentially used in antitumoral therapies. A. One type of antitumoral agents (e.g., cannabinoids)
activates ER stress and autophagy as a mechanism to promote cancer cell death. In these cases, strategies aimed at increasing the stimulation
of ER stress and autophagy might be beneﬁcial; B. Other anticancer agents (e.g., PDT) activate ER stress as part of the mechanisms by which
they promote cancer cell death. Secondary ER stress-induced activation of autophagy may contribute to cell death (in apoptosis-deﬁcient
cells) or to cell survival (in apoptosis competent cells). Thus, depending on the tumor features, autophagy inhibitors or inducers might be
administered to improve the response to these anticancer agents. C. A third type of antitumoral agents (e.g., Imatinib mesilate) activates a
protective ER stress/autophagy response secondarily to its primary antitumoral mechanism. Inhibition of ER stress and/or autophagy would
help to reduce the resistance to this type of therapy.
suggests that diﬀerent signalling routes may converge in the
regulation of autophagy under ER stress situations involving
calcium mobilization [140].
Another link between Ca2+, ER stress, and autophagy
relies on the modulation of the inositol 1,4,5-trisphosphate
receptor (IP3R). This receptor releases Ca2+ from ER stores
in response to diﬀerent cellular signals, although it could
also play additional functions derived from its ability to
interact with diﬀerent proteins, including members of the
Bcl-2 family [141]. Inhibition of the IP3R with xestospon-
gin B [108] or lithium-induced decrease of myo-inositol-
1,4,5-triphosphate (IP3) levels [142] promotes autophagy.
Intriguingly, these eﬀects seem to be independent of the
Ca2+ mobilization function of IP3R [143]. Thus, it has been
recently shown that use of pharmacological inhibitors of the
IP3R disrupts the interaction of this protein with Beclin-1
[144]whichcouldbeanadditionalwayofregulatingthepro-
autophagic function of this protein. Further investigation
is nevertheless necessary to clarify whether this mechanism
participates in the activation of autophagy in response to ER
stress.
3.3. Survival or Death after Autophagy Stimulation by ER
Stress. As discussed for the case of ER stress, autophagy
is currently considered a cell survival mechanism that,
under certain cellular settings, can also promote cell death.
Consequently, depending on whether pharmacological or
genetic inhibition of autophagy enhances or prevents cell
death, activation of autophagy after ER stress has been
assigned respectively a cytotoxic [75, 115, 119, 132, 145–147]
or a protective [5, 6, 115, 119, 128] role. It is worth noting
that depending on the intensity of the stimulus, the cell
type (normal versus cancer cells), and the cellular context,
(hypoxia, starvation, treatment with antitumoral agents, or
presence of mutations) the ﬁnal outcome of autophagy
activation could be diﬀerent.
An important problem at the time of predicting whether
induction of ER stress will activate autophagy in a protective
or cytotoxic way is our relative lack of understanding
of the molecular mechanisms through which autophagy
regulates cell death. Thus, autophagy has been proposed to
protect from apoptosis, operate as an alternative cell death
mechanism (e.g., in cells that are defective in apoptosis), or
act upstream of apoptosis to activate this cellular process,
(reviewed in [133, 148]). As discussed in the previous
section, some of the key regulatory steps in the activation of
autophagy upon stimulation of ER stress (such as mTORC1
inhibition or the interaction of Beclin-1 with Bcl-2) can
also receive signals derived from diﬀerent inputs including
those not directly related with ER stress. Moreover, some
of the regulatory proteins transmitting these signals such as
Akt, AMPK, DAPK, or JNK play also a major role in the
modulation of cell survival independently of autophagy. It is
therefore essential to consider the cellular context in order to
understand how the diﬀerent ER stress signals are integrated
to yield a protective or cytotoxic autophagic response.
4. ER Stress andAutophagy in Anticancer
Therapy: A Double-Edged Sword
From the above discussion, it is clear that ER stress and
autophagy can activate both prosurvival mechanisms as
well as lethal programs, especially under conditions ofInternational Journal of Cell Biology 11
enduring ER stress and organellar damage. Thus activation
of the UPR and autophagy may either impede or facilitate
drug-mediated cell killing, and it is plausible that this
will depend on the type of cancer and cytotoxic agents
used. While a growing number of reports have started to
identify molecular elements of the cross-talk between ER
stress and autophagy (see Section 3.2), thus unraveling
potential druggable targets, knowledge of the functional
outcome of the activation of these pathways in cancer cells
responding to chemotherapeutics is still very limited. In
terms of therapeutic outcome, drugs (or a combination
thereof) capable of activating the proapoptotic branch of
the UPR while simultaneously inhibiting its prosurvival
function should provide the highest therapeutic beneﬁt.
Moreover, if autophagy activated following ER stress is a
survival response restoring ER homeostasis (e.g., by the
removal of protein aggregates), its pharmacological blockage
could protract UPR activation until a critical threshold is
reached, which may precipitate its proapoptotic function.
On the other hand, autophagy may endorse the proapoptotic
functions of certain ER stress pathways (see also Section 4.1)
or become a lethal backup pathway in cancer cells with
defect on apoptotic signaling [133, 148]. (Figure 3).
A wide array of conventional and experimental chemo-
therapeutic agents has been shown to stimulate ER stress
and activation of UPR along with autophagy in cancer
cells. For example, tunicamycin, thapsigargin, and brefeldin
A activate autophagy in colon and prostate cancer cells
thus mitigating ER stress and protecting against cell death.
However, autophagy induced by the same chemicals does
not confer protection in a normal human colon cell line and
in the nontransformed murine embryonic ﬁbroblasts but
rather contributes to cell death [115]. The combined admin-
istration of Vorinostat (a histone deacetylase inhibitor) and
Sorafenib (a tyrosine kinase inhibitor) to carcinoma cells
promotes cell death although activates at the same time
a protective ER stress-driven autophagic response [149].
Similarly, the resistance to Imatinib mesylate (a BCR/ABL
tyrosine kinase inhibitor used for the treatment of chronic
myeloid leukaemia) might also rely—at least in part—on
the secondary activation of ER stress-induced autophagy
[150]. By contrast, cannabinoid treatment activates ER stress
and autophagy leading to apoptotic cell death of glioma
and pancreatic cancer cells but not of nontransformed
embryonic fribroblasts or primary astrocytes (in which
neither ER stress nor autophagy is activated in response to
the treatment with these compounds) [75]. Likewise, other
agents such as Nelﬁnavir (an HIV protease inhibitor with
anticancer activity) [151, 152]o rM e l a n o m ad i ﬀerentiation
associated gene-7/interleukin 24 (mda-7/IL-24) [145, 153]
activate an ER stress response that promotes autophagy
and apoptosis of cancer cells. Increased expression of
Tetraspanins (a family of proteins that facilitate the spatial
organisation and localisation of multiprotein complexes in
distinct membranal microdomains) has also been shown to
activate ER stress and autophagic cell death [154].
Understanding the precise molecular mechanisms that
regulate the extent of autophagy activation in response to
diﬀerent triggering signals as well as the ones that control
the interplay of this cellular process with apoptosis is
therefore crucial to design new antitumoral therapies based
on the modulation of the ER stress-autophagy response.
Here we discuss further a selected group of clinically used
or promising cytotoxic drugs with a demonstrated ability of
inducing both UPR and autophagy, as paradigms to discuss
the potential of targeting these pathways in cancer therapy.
4.1. Cannabinoids. Cannabinoids, the active components of
marijuana, of which THC is the most important owing to
its high abundance and potency [155], exert a wide variety
of biological eﬀects by mimicking endogenous substances,
the endocannabinoids, that bind to and activate speciﬁc
cannabinoid receptors [156]. Cannabinoids are currently
being investigated as potential antitumoral agents. Thus,
treatment with these agents has been shown to curb tumor
growth in various animal models of cancer [157–159]. The
antitumoral action of cannabinoids is based on the ability
of these agents to inhibit tumor angiogenesis and activate
apoptosis of cancer cells [157, 158].
Our recent ﬁndings have unravelled that cannabinoids
induce autophagy in diﬀerent types of tumor cells, including
glioma/astrocytoma and pancreatic cancer cells, whereas
they do not activate this cellular process in nontransformed
cells (which are resistant to the cell death-promoting activity
of cannabinoids) [75]. Of interest, pharmacological or
genetic inhibition of autophagy prevented cannabinoid-
inducedcelldeathaswellasapoptosis,whereasabrogationof
apoptosis prevented cell death but not autophagy as induced
by these agents. These observations led us to conclude
that induction of autophagy is part of the mechanism
by which cannabinoids promote the apoptotic death of
cancer cells. The in vivo relevance of these ﬁndings was
demonstrated by the observation that cannabinoid treat-
ment reduced tumor growth and activated autophagy and
apoptosis in subcutaneous tumor xenografts derived from
human U87MG astrocytoma cells and transformed mouse
embryonic ﬁbroblasts (MEFs). Likewise, similar results have
been obtained in an orthotopic model of pancreatic cancer,
in which we had previously shown a proapoptotic and an
antitumoral action of cannabinoids ([122, 123], Salazar, M.
and Velasco G., unpublished observations). Furthermore,
autophagy-deﬁcient tumors (generated by subcutaneous
injection of transformed Atg5−/− MEFs) were resistant to
THCantitumoralaction,stronglysupportingthatautophagy
is essential for the antineoplastic activity of cannabinoids. In
addition,analysisofsamplesobtainedfromtwoglioblastoma
multiforme patients indicated that THC administration
might also trigger autophagy-mediated cell death in human
tumors [75].
As discussed in the previous section, the mechanism
responsible for the activation of autophagy upon THC
administration relies on a cannabinoid receptors-induced
early accumulation of de novo-synthesized ceramide [an
event that takes place in the ER [160]], which leads in
turn to ER dilation and increased eIF2α phosphorylation
[75]. Activation of this ER stress response induces the up-
regulation of several genes, including the stress-regulated
protein p8 and its downstream targets ATF-4 and CHOP12 International Journal of Cell Biology
and the pseudokinase TRB3, which are required for the
stimulation of autophagy in response to cannabinoid action.
TRB3 plays a crucial role in the induction of autophagy
upon THC administration through its inhibitory interaction
with Akt, which leads in turn to mTORC1 inhibition. In
agreement with these observations, treatment of mice with
THC decreased mTORC1 activity, stimulated autophagy
and apoptosis, and reduced tumor growth in xenografts
generated with p8+/+ cells but not in those generated with
p8−/− cells(inwhichTRB3isnotup-regulatedinresponseto
THC [122]), further conﬁrming that the p8/TRB3 pathway
plays an essential role in the activation of autophagy and cell
death by cannabinoids also in vivo.
Cannabinoids activate therefore a cell death-promoting
signalling route that involves the stimulation of ER stress,
autophagy, and apoptosis in cancer cells. Thus, cannabinoids
constitute an interesting tool to investigate the diﬀerential
molecular mechanisms that are responsible for the stimula-
tion of autophagy-mediated cell death. On the other hand,
the selectivity of cannabinoids (which only stimulate the
above-described cell death promoting pathway in cancer
cells) together with a low toxicity and good safety proﬁle
makes of these agents promising antineoplastic tools.
4.2.Photodynamic Therapy. Photodynamic therapy (PDT)is
an anticancer therapy involving the selective photosensitiza-
tion of malignant cell types, usually involving porphyrins,
porphyrin analogs or other agents with suitable photo-
physical properties. The initial step in the photodynamic
process involves localization of the photosensitizing agent
at subcellular loci, followed by irradiation with visible light
of the appropriate wavelength [161, 162]. This results in
formation of singlet oxygen and other ROS that can cause
photodamage at sites where the photosensitizing agent has
localized. Since singlet oxygen will not migrate more than a
fraction of a micron from the site of formation, as a result,
photodamage can be quite speciﬁc. Thus, a distinguished
property of PDT is that ROS formation is mainly targeted
to a particular subcellular site and aﬀects a rather speciﬁc
subset of molecular targets. PDT with various agents has
been shown to induce apoptosis along with autophagy and,
in most cases, autophagy is activated as a mean to protect
cells from killing [8]. Agents found to be clinically useful
were reported to show aﬃnity for the ER, mitochondria,
lysosomes, or combinations of these sites [163]. A well-
studied paradigm of ER-localizing dye is hypericin, a nat-
urally occurring phototoxin with promising applications
in bladder cancer [164]. Consistent with its predominant
reticular localization in cultured cells [82], light activation of
hypericin is coupled with massive ER expansion, preceding
ultrastructural features of apoptosis, both in vitro and in
bladder cancer bearing rats (Verfaillie, T. and Agostinis, P.
unpublished observations), and stimulation of UPR [165].
UPR activation is likely the result of immediate ROS-damage
to the SERCA pump, depleting ER-Ca2+ store, which is
followed by the concomitant activation of autophagy and
mitochondrial apoptosis [82]. This ROS paradigm of ER
stress is linked to a persistent activation of the PERK-
eIF2α-CHOP axis, with proapoptotic function (Verfaillie, T.
and Agostinis, P. unpublished observations). Induction of
autophagy in ER stressed cells unable to mount an apoptotic
response (because of bax/bak deﬁciency) results in increased
photokilling, suggesting the activation of an “autophagic cell
death” pathway [82]. Conversely, in apoptosis-competent
cells, blocking autophagy stimulation following ER stress by
siRNAs that target essential modulators of the autophagic
machinery, sensitizes to cell death, thus revealing a cytopro-
tective role for this pathway (Dewaele, M. and Agostinis, P.
unpublished results). Hence, it is tempting to speculate that
autophagy inhibition may potentiate the proapoptotic PERK
pathway resulting in a better therapeutic opportunity, only
whenthecancercell’sapoptoticmachineryhasnotbeenfully
disabled. Further studies are required to establish whether
suppression of the autophagic pathway along with UPR
stimulation may represent a valuable therapeutic strategy in
hypericin-based PDT.
4.3. Proteasome Inhibitors. Targeting proteasomal degrada-
tion has proven to be a valuable approach in various cancer
treatments, and proteasome inhibitors have emerged as a
new class of ER stress agents. Moreover, recent evidence
suggests that when used in combination with certain
cytotoxic drugs, such as PDT, proteasomal inhibitors are
capable of enhancing their anticancer eﬃcacy, making these
agents a very promising class of pharmacological agents in
combinatorial therapy.
4.3.1. Bortezomib. Bortezomib (PS-341 or Velcade) dis-
tinguishes itself from other proteasome inhibitors as it
speciﬁcally inhibits the 26S proteasome by selectively block-
ing its chymotryptic activity. Velcade has been clinically
approved for treatment of multiple myeloma and mantle
cell lymphoma [166, 167] and has been shown to success-
fully induce apoptosis in various human cancer cell lines
including myeloma, prostate, and breast cancers as well
as squamous cell carcinoma [168–170]. Moreover, preclin-
ical studies indicate that bortezomib displays anticancer
activity against pancreatic cancers [171], one of the most
aggressive human diseases. One of the potential mechanisms
underlying the apoptotic eﬀects of bortezomib in cancer
cells relies on its ability to inhibit the NF-κBp a t h w a y
by blocking the degradation of its cytoplasmic inhibitor
IκBα [172]. However, inhibition of NF-κB alone could
not fully account for the antitumor eﬀect by bortezomib,
suggesting additional pathways being involved [173]. This
additional pathway turned out to be dependent on ER
stress. Since proteasomal degradation of misfolded proteins
retrotranslocated from the ER to the cytosol represents
the ﬁnal step in ERAD, proteasomal inhibition causes an
additional burden of unfolded proteins on the ER. This
explains the high eﬃcacy of bortezomib treatment against
types of cancer cells in which the ER is already predisposed
with a considerable load. For instance, hypoxic cancer
cells that otherwise show increased resistance to genotoxic
agents as well as myeloma cells producing high amounts
of immunoglobulins are hypersensitive to treatment with
proteasome inhibitors [174, 175]. Therefore, therapies thatInternational Journal of Cell Biology 13
target the ER response in combination with bortezomib
ought to be more successful. Indeed, it was shown that
bortezomib sensitized pancreatic cancer cells to ER stress
mediated apoptosis [176]. Additionally, we recently found
a signiﬁcant retardation of tumor growth in vivo in two
diﬀerent murine tumor models when photofrin-based PDT,
a PDT approach stimulating the UPR, was combined with
bortezomib, or other clinically used proteasome inhibitors
[177].Thissuggeststhatblockingtheproteasomemightoﬀer
a new therapeutic avenue to potentiate the antitumor eﬀect
of PDT.
Interestingly, Schewe and Aguirre-Ghiso [178]f o u n d
that myeloma cells surviving bortezomib treatment atten-
uated eIF2α phosphorylation and induction of CHOP.
Combined treatment with the GADD34-PP1 complex
inhibitor salubrinal restored eIF2α phosphorylation and
CHOP induction, maximizing bortezomib induced apop-
tosis, thus suggesting that strategies capable of sustaining
CHOPexpression might berequiredto successfullyeradicate
tumors.
Aside from proteasomal degradation, autophagy repre-
sents another important mechanism for degrading intracel-
lular material. Furthermore, these processes are functionally
coupled and proteasomal inhibition has been shown to
stimulate autophagy, likely as a compensatory mechanism
[119]. Surprisingly, whether autophagy enhances apoptosis
inducedbyproteasomalinhibitorsornotseemstodependon
whether the treated cells are transformed or not [179]. These
ﬁndings suggest that a combined inhibition of both cellular
degradation systems would enhance the antitumoral eﬃcacy.
Indeed, autophagy was shown to be activated in MCF-7 cells
treated with bortezomib, by a mechanism which involved
proteasomal stabilization of ATF4 and ATF4 dependent
upregulation of LC3B. This mechanism was suggested to
contribute to the resistance of breast cancer cells towards
bortezomib[180].However,arecentstudywhereinmyeloma
cells where treated with bortezomib in combination with the
autophagy inhibitor 3-methyl adenine (3-MA) resulted in
an antagonistic response instead of the expected synergizing
eﬀect [181].
5. Conclusions
Research during the last decade has contributed to high-
light the important role of ER stress and autophagy in
the maintenance of the cellular homeostasis. The last few
years have also evidenced that both processes are closely
related as some of the signalling routes activated during the
ER stress response are involved in stimulating autophagy.
Intriguingly, activation of autophagy after ER stress can be
either protective of cytotoxic. For example, accumulation of
unfoldedproteinsinneurodegenerativediseasesmayactivate
a protective autophagy response. By contrast induction of
ER stress in cancer cells may promote the stimulation
of autophagy-mediated cell death or the activation of a
protective autophagy that may contribute to the resistance
to certain antitumoral therapies. Thus, diﬀerent factors such
as the intensity of the ER stress signal, the simultaneous
activation of additional pathways, the cell type, and so forth,
must be integrated to yield a speciﬁc autophagic response.
Considering that escape from drug-mediated cell killing is
one of the major obstacles of current cancer therapy, a better
understanding of the role played by these processes in cancer
cells in response to chemotherapy would help us to devise
new and more eﬃcient therapeutic opportunities utilizing
inhibitors or activators of these ER stress pathways.
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